CytomX Therapeutics (NASDAQ:CTMX) Given New $16.00 Price Target at Barclays

CytomX Therapeutics (NASDAQ:CTMX) had its price objective raised by Barclays from $10.00 to $16.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

A number of other analysts also recently weighed in on CTMX. Guggenheim boosted their target price on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright increased their price target on shares of CytomX Therapeutics from $10.00 to $17.00 and gave the company a “buy” rating in a report on Monday. Jefferies Financial Group increased their price target on shares of CytomX Therapeutics from $8.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $7.00 to $12.00 in a research note on Monday. Finally, Cantor Fitzgerald boosted their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.22.

CytomX Therapeutics Stock Performance

CTMX stock opened at $4.77 on Thursday. The firm has a fifty day moving average price of $5.28 and a 200 day moving average price of $4.10. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $8.21. The firm has a market cap of $810.96 million, a PE ratio of -119.13 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The business had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million. CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%. On average, equities analysts predict that CytomX Therapeutics will post -0.05 EPS for the current year.

Insider Activity

In other news, CEO Sean A. Mccarthy sold 118,969 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $763,780.98. Following the completion of the sale, the chief executive officer owned 1,078,922 shares in the company, valued at approximately $6,926,679.24. This trade represents a 9.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Marcia Belvin sold 31,492 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $202,178.64. Following the transaction, the senior vice president directly owned 300,760 shares of the company’s stock, valued at approximately $1,930,879.20. This represents a 9.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 191,063 shares of company stock worth $1,226,624. 6.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC purchased a new stake in shares of CytomX Therapeutics in the third quarter worth approximately $25,000. Wells Fargo & Company MN lifted its stake in shares of CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,000 shares during the last quarter. Invesco Ltd. purchased a new position in CytomX Therapeutics during the 2nd quarter valued at $32,000. Pursue Wealth Partners LLC bought a new position in CytomX Therapeutics in the 2nd quarter valued at $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in CytomX Therapeutics in the 3rd quarter valued at $34,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics News Summary

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Several brokerages raised ratings/targets, boosting sentiment — Barclays raised its target to $16 (overweight). Article Title
• Positive Sentiment: Guggenheim increased its price target to $15 and kept a Buy rating, supporting upside expectations. Article Title
• Positive Sentiment: Wedbush raised its price target to $11, and JPMorgan reportedly upgraded the stock — multiple upgrades are driving positive analyst momentum. Wedbush Article JPMorgan Article
• Neutral Sentiment: HC Wainwright cut near‑term EPS forecasts (Q1–Q4 2026 and FY2026/2027) but retained a Buy rating and a $17 target — mixed signal (lowered estimates but continued bullish view). MarketBeat Report
• Neutral Sentiment: Short-interest data in the feed appears anomalous (shows zero shares) and likely does not provide meaningful directional signal today.
• Negative Sentiment: CytomX priced an underwritten offering of common stock and pre‑funded warrants to raise up to $250M gross (closing expected March 19); markets often view such equity raises as dilutive, which can pressure the stock despite providing runway for trials. Offering Release
• Negative Sentiment: Related coverage notes net proceeds of about $234M from the offering — confirms material dilution magnitude and why some traders sold into the raise. TipRanks Article
• Negative Sentiment: Insider selling: CFO Christopher Ogden sold 19,323 shares and SVP Marcia Belvin sold 31,492 shares on March 17 — disclosed on SEC Form 4 filings; insider sales can be read negatively by the market. CFO Form 4 SVP Form 4
• Negative Sentiment: Recent quarterly results missed expectations (EPS and revenue), which was cited as a reason for an intra‑day pullback earlier this week. Earnings Reaction

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.